Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE 80 25 versus RESNIBEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE 80 25 versus RESNIBEN.
INDERIDE-80/25 vs RESNIBEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
RESNIBEN is a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
1 mg orally once daily, increased to 2 mg once daily based on response and tolerability; maximum 2 mg daily.
None Documented
None Documented
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Terminal elimination half-life is 6-8 hours in healthy adults, prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min).
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Primarily renal excretion (65-70% as unchanged drug), with biliary/fecal elimination accounting for 20-25% (including metabolites).
Category C
Category C
Beta Blocker and Thiazide Diuretic
Thiazide Diuretic